Preventive effects of nitroglycerine on glucocorticoid-induced osteoporosis in growing rats.
The preventive effects of nitroglycerine (NG) on glucocorticoid-induced osteoporosis in growing rats were studied. Three-month-old female Wistar rats were randomly divided into control group (CON), dexamethasone group (DXM), DXM plus a low dose NG group (NG-L), DXM plus a middle dose NG group (NG-M) and DXM plus a high dose NG group (NG-H), 8 rats in each group. The rat model of osteoporosis was developed by intramuscular injection of dexamethasone twice a week. NG 0.2, 0.4 and 1.0 mg/kg was administered by oral gavages to the treatment groups every day for 12 weeks. Rats in CON group and DXM group were treated with normal saline of the same amount. After the treatment, the bone mineral density (BMD) and bone metabolism-associated biochemical markers were determined. Compared with CON group, BMD of lumbar spine and femur in DXM group was decreased significantly (P<0.05 and P<0.01 respectively), blood BGP levels and NO levels reduced (both P<0.01), and TRAP level increased (P<0.05). As compared with DXM group, BMD, serum BGP and NO were increased, and TRAP decreased in NG-L group and NG-M group, but had no significant difference in comparison to CON group. All the markers other than serum NO and TRAP levels had no significant difference between NG-H group and DXM group. It was concluded that low or middle doses of NG could prevent glucocorticoid-induced bone loss in growing rats, but high dose of NG could not. Supplement with NO donor could be considered as a preventive treatment for glucocorticoid-induced osteoporosis in a developing skeleton.
Li
Yuming
Y
Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. lym.1020@163.com
Li
Yongguo
Y
Yang
Weihong
W
D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D003907:Dexamethasone; D005260:Female; D020030:Nitric Oxide Donors / Q000627:therapeutic use*; D005996:Nitroglycerin / Q000494:pharmacology / Q000627:therapeutic use*; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
D020030:Nitric Oxide Donors; D003907:Dexamethasone; D005996:Nitroglycerin